Taysha Gene Therapies, Inc.
TSHA · Nasdaq · USD · Market cap $1.3B · 99 employees
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central ner…
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price3.72 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 3.00x the price, above our 2.00x limit.
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.65)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.65, read 2026-11-18
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Taysha Gene Therapies, Inc. holds its Accumulation at $3.72. The statistical read favours the sellers, held for 6 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 6 days |
| Price at the screen | $3.72 |
| Valuation | N/A trailing · -10.32 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.31 |
Five Screens: TSHA's Results
FAIL. Accounts receivable
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 20.43% | Below 33% | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 93.14% | Below 49% | Fail |
| Revenue purity | 94.38% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Taysha Gene Therapies,'s business is fine, but its receivables are about 93% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when TSHA's ethical verdict changes
Today TSHA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 3.00x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 13 covering, consensus Strong Buy. Average target +223%.
| Forward P/E | -10.3x |
| EPS, trailing | -0.42 |
| EPS, forward | -0.39 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -54.2%not currently earning a positive return on equity |
| FCF yield | -6.92% |
| Debt to equity | 0.15minimal debt: a conservative balance sheet |
| Current ratio | 18.56comfortably covers its short-term bills |
| Beta | 1.31moves a little more than the market |
| Short interest, float | 0.17% |
| 52-week range | 3.46 - 7.30 |
| Market cap | $1.3B |
| Employees | 99 |
TSHA-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markup to accumulation since the last review.
The framework has shifted from distribution to markup since the last review.
The framework has shifted from markup to distribution since the last review.
The framework has shifted from distribution to markup since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Taysha (TSHA) Q3 2026 Earnings Call Transcript Yahoo Finance · 8d ago
- Taysha Gene Therapies Q3 Earnings Call Highlights Yahoo Finance · 9d ago
- Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update Yahoo Finance · 9d ago
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance · 15d ago
- Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 Yahoo Finance · 16d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $6.82 | -20.8% | · | $792 | -20.8% |
| 2 months | $4.49 | +20.3% | · | $1,203 | +20.3% |
| 3 months | $4.61 | +17.1% | · | $1,171 | +17.1% |
| 6 months | $5.76 | -6.3% | · | $938 | -6.3% |
| 1 year | $2.61 | +106.9% | · | $2,069 | +106.9% |
| 2 years | $3.92 | +37.8% | · | $1,378 | +37.8% |
| 3 years | $0.86 | +527.9% | · | $6,279 | +527.9% |
| 5 years | $24.51 | -78.0% | · | $220 | -78.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TSHA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.